Pharmaceutical Research and Manufacturers of America Sustainability Profile
The Pharmaceutical Research and Manufacturers of America (PhRMA) is a leading trade association based in the United States, representing the innovative biopharmaceutical industry. Founded in 1958, PhRMA advocates for policies that foster medical innovation and improve patient access to life-saving medications. With a strong presence across major operational regions in the US, PhRMA focuses on key areas such as drug discovery, development, and market access. PhRMA's core services include research advocacy, policy development, and educational initiatives aimed at promoting the value of pharmaceuticals. The organisation is recognised for its commitment to advancing public health through innovation, evidenced by its members' contributions to groundbreaking therapies and vaccines. As a prominent voice in the biopharmaceutical sector, PhRMA plays a crucial role in shaping the future of healthcare and ensuring that patients benefit from the latest medical advancements.
DitchCarbon Score
How does Pharmaceutical Research and Manufacturers of America's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Membership Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaceutical Research and Manufacturers of America's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmaceutical Research and Manufacturers of America's reported carbon emissions
The Pharmaceutical Research and Manufacturers of America (PhRMA), headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the organisation. As such, PhRMA's climate commitments and initiatives remain unspecified, and there is no inherited emissions data from a parent or related organisation. The lack of publicly available information on emissions and reduction strategies highlights a potential area for improvement in transparency and accountability within the pharmaceutical sector regarding climate action.
How Carbon Intensive is Pharmaceutical Research and Manufacturers of America's Industry?
How Carbon Intensive is Pharmaceutical Research and Manufacturers of America's Location?
Pharmaceutical Research and Manufacturers of America's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmaceutical Research and Manufacturers of America has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
